Cargando…
Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
Since the end of the1990ies, Cyprinid herpesvirus 3 (also known as koi herpesvirus, KHV) has caused mass mortality events of koi and common carp all over the globe. This induced a high economic impact, since the KHV disease cannot be cured up to now, but only prevented by vaccination. Unfortunately,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448810/ https://www.ncbi.nlm.nih.gov/pubmed/36068296 http://dx.doi.org/10.1038/s41541-022-00525-6 |
_version_ | 1784784148964048896 |
---|---|
author | Klafack, Sandro Schröder, Lars Jin, Yeonhwa Lenk, Matthias Lee, Pei-Yu Fuchs, Walter Avarre, Jean-Christophe Bergmann, Sven M. |
author_facet | Klafack, Sandro Schröder, Lars Jin, Yeonhwa Lenk, Matthias Lee, Pei-Yu Fuchs, Walter Avarre, Jean-Christophe Bergmann, Sven M. |
author_sort | Klafack, Sandro |
collection | PubMed |
description | Since the end of the1990ies, Cyprinid herpesvirus 3 (also known as koi herpesvirus, KHV) has caused mass mortality events of koi and common carp all over the globe. This induced a high economic impact, since the KHV disease cannot be cured up to now, but only prevented by vaccination. Unfortunately, there is only one commercial vaccine available which is not approved in most countries. Therefore, there is an urgent need for new, safe and available vaccines. In this study, a live attenuated vaccine virus was generated by cell culture passages of virulent KHV, and shown to protect carp or koi after immersion or oral application against wild type challenge. An advantage of boost immunization was demonstrated, especially after oral application. Vaccination induced no or mild clinical signs and protecting antibodies have been measured. Additionally, the vaccine virus allowed differentiation of infected from vaccinated animals (DIVA) by PCR. The attenuation of the newly generated vaccine was tracked down to a partial deletion of open reading frame 150. This was confirmed by the generation of engineered ORF150 deletion mutants of wild-type KHV which exhibited a similar attenuation in vivo. |
format | Online Article Text |
id | pubmed-9448810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-94488102022-09-08 Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion Klafack, Sandro Schröder, Lars Jin, Yeonhwa Lenk, Matthias Lee, Pei-Yu Fuchs, Walter Avarre, Jean-Christophe Bergmann, Sven M. NPJ Vaccines Article Since the end of the1990ies, Cyprinid herpesvirus 3 (also known as koi herpesvirus, KHV) has caused mass mortality events of koi and common carp all over the globe. This induced a high economic impact, since the KHV disease cannot be cured up to now, but only prevented by vaccination. Unfortunately, there is only one commercial vaccine available which is not approved in most countries. Therefore, there is an urgent need for new, safe and available vaccines. In this study, a live attenuated vaccine virus was generated by cell culture passages of virulent KHV, and shown to protect carp or koi after immersion or oral application against wild type challenge. An advantage of boost immunization was demonstrated, especially after oral application. Vaccination induced no or mild clinical signs and protecting antibodies have been measured. Additionally, the vaccine virus allowed differentiation of infected from vaccinated animals (DIVA) by PCR. The attenuation of the newly generated vaccine was tracked down to a partial deletion of open reading frame 150. This was confirmed by the generation of engineered ORF150 deletion mutants of wild-type KHV which exhibited a similar attenuation in vivo. Nature Publishing Group UK 2022-09-06 /pmc/articles/PMC9448810/ /pubmed/36068296 http://dx.doi.org/10.1038/s41541-022-00525-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Klafack, Sandro Schröder, Lars Jin, Yeonhwa Lenk, Matthias Lee, Pei-Yu Fuchs, Walter Avarre, Jean-Christophe Bergmann, Sven M. Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion |
title | Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion |
title_full | Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion |
title_fullStr | Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion |
title_full_unstemmed | Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion |
title_short | Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion |
title_sort | development of an attenuated vaccine against koi herpesvirus disease (khvd) suitable for oral administration and immersion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448810/ https://www.ncbi.nlm.nih.gov/pubmed/36068296 http://dx.doi.org/10.1038/s41541-022-00525-6 |
work_keys_str_mv | AT klafacksandro developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT schroderlars developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT jinyeonhwa developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT lenkmatthias developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT leepeiyu developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT fuchswalter developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT avarrejeanchristophe developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion AT bergmannsvenm developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion |